{"id":3108,"date":"2019-07-27T03:16:22","date_gmt":"2019-07-27T03:16:22","guid":{"rendered":"https:\/\/www.asadkarim.co.uk\/?p=3108"},"modified":"2019-07-25T08:18:11","modified_gmt":"2019-07-25T08:18:11","slug":"the-lg-pharma-breakthrough-etf","status":"publish","type":"post","link":"https:\/\/www.asadkarim.co.uk\/?p=3108","title":{"rendered":"The L&#038;G Pharma Breakthrough ETF"},"content":{"rendered":"\n<p>The L&amp;G Pharma Breakthrough UCITS ETF is an Exchange Traded Fund that owns shares in pharmaceutical companies, that looks for Long-term value in the pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives. <\/p>\n\n\n\n<p><a href=\"https:\/\/fundcentres.lgim.com\/srp\/documents-id\/9c1df141-4b11-414b-a098-b5934daf6dce\/Fact-sheet_LG-Pharma-Breakthrough-UCITS-ETF-Pharma-Breakthrough-USD-Acc.pdf\">https:\/\/fundcentres.lgim.com\/srp\/documents-id\/9c1df141-4b11-414b-a098-b5934daf6dce\/Fact-sheet_LG-Pharma-Breakthrough-UCITS-ETF-Pharma-Breakthrough-USD-Acc.pdf<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>It&#8217;s top ten holdings are:- <\/p>\n\n\n\n<p>Array BioPharma 6.6% of the fund <\/p>\n\n\n\n<p>PTC Therapeutics 4.2% of the fund <\/p>\n\n\n\n<p>PharmaMar 4.0% of the fund <\/p>\n\n\n\n<p>Grifols 3.7% of the fund <\/p>\n\n\n\n<p>CSL 3.6% of the fund <\/p>\n\n\n\n<p>Nippon Shinyaku 3.6% of the fund <\/p>\n\n\n\n<p>Celgene 3.6% of the fund <\/p>\n\n\n\n<p>Jazz Pharmaceuticals 3.4% of the fund <\/p>\n\n\n\n<p>Novartis 3.3% of the fund <\/p>\n\n\n\n<p>Ipsen 3.3% of the fund<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/www.shareshop.hsbc.co.uk\/shareshop\/security.cgi?csi=54634586&amp;action=\">https:\/\/www.shareshop.hsbc.co.uk\/shareshop\/security.cgi?csi=54634586&amp;action=<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The L&amp;G Pharma Breakthrough UCITS ETF is an Exchange Traded Fund that owns shares in pharmaceutical companies, that looks for Long-term value in the pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives. https:\/\/fundcentres.lgim.com\/srp\/documents-id\/9c1df141-4b11-414b-a098-b5934daf6dce\/Fact-sheet_LG-Pharma-Breakthrough-UCITS-ETF-Pharma-Breakthrough-USD-Acc.pdf It&#8217;s top ten holdings are:- Array BioPharma 6.6% of the fund PTC Therapeutics 4.2% of the fund PharmaMar 4.0% of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3108","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/3108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3108"}],"version-history":[{"count":1,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/3108\/revisions"}],"predecessor-version":[{"id":3109,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/3108\/revisions\/3109"}],"wp:attachment":[{"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.asadkarim.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}